HRP20200969T1 - Ligandi koji potenciraju bioaktivnost gonadotropina - Google Patents
Ligandi koji potenciraju bioaktivnost gonadotropina Download PDFInfo
- Publication number
- HRP20200969T1 HRP20200969T1 HRP20200969TT HRP20200969T HRP20200969T1 HR P20200969 T1 HRP20200969 T1 HR P20200969T1 HR P20200969T T HRP20200969T T HR P20200969TT HR P20200969 T HRP20200969 T HR P20200969T HR P20200969 T1 HRP20200969 T1 HR P20200969T1
- Authority
- HR
- Croatia
- Prior art keywords
- ligand
- sequence
- seq
- fsh
- variable domain
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims 24
- 239000002622 gonadotropin Substances 0.000 title claims 2
- 102000006771 Gonadotropins Human genes 0.000 title 1
- 108010086677 Gonadotropins Proteins 0.000 title 1
- 229940094892 gonadotropins Drugs 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 14
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 14
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 14
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 11
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 11
- 229940015047 chorionic gonadotropin Drugs 0.000 claims 11
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 10
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 10
- 229940040129 luteinizing hormone Drugs 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 2
- 230000016087 ovulation Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (17)
1. Ligand folikula-stimulirajućeg hormona (FSH) koji potencira bioaktivnost FSH, luteinizirajućeg hormona (LH) i korionskog gonadotropina (CG), naznačen time što je navedeni ligand antitijelo ili njegov fragment i da:
varijabilna domena teškog lanca sadrži sljedeće CDRs:
- VH-CDR1, definiran sekvencijom GFTFSDFY (SEQ ID NO: 9);
- VH-CDR2, definiran sekvencijom SRNKAKDYTT (SEQ ID NO: 10);
- VH-CDR3, definiran sekvencijom ARDARFAY (SEQ ID NO: 11); i
varijabilna domena lakog lanca sadrži sljedeće CDRs:
- VL-CDR1, definiran sekvencijom QSLLYSSNQKNY (SEQ ID NO: 12);
- VL-CDR2, definiran sekvencijom WAS; i
- VL-CDR3, definiran sekvencijom QQYYSYPRT (SEQ ID NO: 13).
2. Ligand folikulo-stimulirajućeg hormona (FSH) koji potencira bioaktivnost FSH, luteinizirajućeg hormona (LH) i korionskog gonadotropina (CG), naznačen time što je navedeni ligand antitijelo ili njegov fragment i da:
- varijabilna domena teškog lanca sadrži sekvenciju SEQ ID NO: 2 ili 47; i/ili
- varijabilna domena lakog lanca sadrži sekvenciju SEQ ID NO: 4 ili 45.
3. Ligand folikula-stimulirajućeg hormona (FSH) koji potencira bioaktivnost FSH, luteinizirajućeg hormona (LH) i korionskog gonadotropina (CG), naznačen time što je navedeni ligand antitijelo ili njegov fragment i da:
varijabilna domena teškog lanca sadrži sljedeće CDRs:
- VH-CDR1, definiran sekvencijom GFTFNTYA (SEQ ID NO: 14);
- VH-CDR2, definiran sekvencijom IRSKSNNYAT (SEQ ID NO: 15);
- VH-CDR3, definiran sekvencijom VRQDYYGSSYFDY (SEQ ID NO: 16); i
varijabilna domena lakog lanca sadrži sljedeće CDRs:
- VL-CDR1, definiran sekvencijom QSISDY (SEQ ID NO: 17);
- VL-CDR2, definiran sekvencijom YAS; i
- VL-CDR3, definiran sekvencijom QNGHSFPYT (SEQ ID NO: 18).
4. Folikula-stimulirajući hormon (FSH) ligand koji potencira bioaktivnost FSH, luteinizirajućeg hormona (LH) i korionskog gonadotropina (CG), naznačen time što je navedeni ligand antitijelo ili njegov fragment i da:
- varijabilna domena teškog lanca sadrži sekvenciju SEQ ID NO: 6;
i/ili
- varijabilna domena lakog lanca sadrži sekvenciju SEQ ID NO: 8.
5. Ligand sukladno bilo kojem od zahtjeva 1 do 4, naznačen time što je ligand odabran iz skupine sastavljene od Fab, Fab’, F(ab’)2, Fv, dsFv, scFv, dijatijela, trijatijela, tetratijela.
6. Ligand sukladno zahtjevu 1, naznačen time što je ligand CA5 monoklonsko antitijelo koje proizvodi CNCM I-4801 hibridoma.
7. Ligand sukladno zahtjevu 3, naznačen time što je ligand CH10 monoklonsko antitijelo koje proizvodi CNCM hibridom I-4802.
8. Ligand sukladno zahtjevu 5, naznačen time što je peptidna sekvencija scFv sekvencija SEQ ID NO: 20 ili SEQ ID NO: 22.
9. Ligand sukladno bilo kojem od zahtjeva 1 do 8, da se upotrebljava kao lijek.
10. Kompleks ligand-gonadotropin sukladno bilo kojem od zahtjeva odabran između:
kompleks liganda sukladno bilo kojem od zahtjeva 1 do 8 sa FSH ili njegovim aktivnim peptidom;
kompleks liganda sukladno bilo kojem od zahtjeva 1 do 8 s LH ili korionskim gonadotropinskim (CG) hormonom, ili aktivnim peptidom navedenog hormona.
11. Kompleks sukladno zahtjevu 10, da se upotrebljava kao lijek.
12. Ligand za uporabu sukladno zahtjevu 9 ili kompleks za uporabu sukladno zahtjevu 11, pri čemu je navedeni lijek namijenjen da inducira ovulaciju ili poliovulaciju u ženskog sisavca.
13. Ligand za uporabu sukladno zahtjevu 9 ili kompleks za uporabu sukladno zahtjevu 11, pri čemu je navedeni lijek namijenjen povećati razinu endogenog progesterone u cirkulaciji u ženskog sisavca.
14. Farmaceutski pripravak namijenjen za primjenu za indukciju ovulacije ili poliovulacije u ženskog sisavca, naznačena time što sadrži ligand sukladno bilo kojem od zahtjeva 1 do 8 i/ili kompleks sukladno zahtjevu 10 i farmaceutski prihvatljivi nosač.
15. Farmaceutski pripravak u primjeni sukladno zahtjevu 14, naznačeno time što također sadrži FSH, LH i/ili CG.
16. Ligand sukladno bilo kojem od zahtjeva 1 do 8 ili kompleks sukladno zahtjevu 10, za liječenje i/ili prevenciji neplodnosti ili hipofertiliteta u ženskog sisavca.
17. Ligand sukladno bilo kojem od zahtjeva 1 do 8 ili kompleks sukladno zahtjevu 10, za primjenu u stimulaciji reprodukcije kod zdrave ženke sisavca.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1458469A FR3025517B1 (fr) | 2014-09-10 | 2014-09-10 | Ligands potentialisants de la bioactivite des gonadotrophines |
FR1558078A FR3025518B1 (fr) | 2014-09-10 | 2015-08-31 | Ligands potentialisants de la bioactivite des gonadotrophines |
EP15770570.8A EP3191514B1 (fr) | 2014-09-10 | 2015-09-10 | Ligands potentialisants de la bioactivite des gonadotrophines |
PCT/FR2015/052414 WO2016038309A1 (fr) | 2014-09-10 | 2015-09-10 | Ligands potentialisants de la bioactivite des gonadotrophines |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200969T1 true HRP20200969T1 (hr) | 2020-10-16 |
Family
ID=52589468
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200969TT HRP20200969T1 (hr) | 2014-09-10 | 2020-06-18 | Ligandi koji potenciraju bioaktivnost gonadotropina |
HRP20210141TT HRP20210141T1 (hr) | 2014-09-10 | 2021-01-26 | Ligandi koji pojačavaju bioaktivnost gonadotropina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210141TT HRP20210141T1 (hr) | 2014-09-10 | 2021-01-26 | Ligandi koji pojačavaju bioaktivnost gonadotropina |
Country Status (21)
Country | Link |
---|---|
US (2) | US10703815B2 (hr) |
EP (2) | EP3191514B1 (hr) |
JP (2) | JP6705608B2 (hr) |
KR (1) | KR102072650B1 (hr) |
CN (2) | CN107108731B (hr) |
AU (1) | AU2015314029C1 (hr) |
BR (1) | BR112017004739B1 (hr) |
CA (2) | CA2960132C (hr) |
CY (2) | CY1123168T1 (hr) |
DK (2) | DK3191515T3 (hr) |
ES (2) | ES2845674T3 (hr) |
FR (2) | FR3025517B1 (hr) |
HR (2) | HRP20200969T1 (hr) |
HU (2) | HUE053100T2 (hr) |
IL (1) | IL250978B2 (hr) |
LT (2) | LT3191514T (hr) |
PL (2) | PL3191515T3 (hr) |
PT (2) | PT3191514T (hr) |
RS (2) | RS61358B1 (hr) |
SI (2) | SI3191515T1 (hr) |
WO (2) | WO2016038308A1 (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3025517B1 (fr) | 2014-09-10 | 2016-12-23 | Repropharm | Ligands potentialisants de la bioactivite des gonadotrophines |
WO2017192847A1 (en) * | 2016-05-04 | 2017-11-09 | University Of Cincinnati | Female fertility therapies |
CN113164190B (zh) * | 2018-10-10 | 2022-07-29 | 茵诺梅得第七有限责任公司 | 用于子宫内授精的系统和方法 |
JP6952219B1 (ja) * | 2019-11-18 | 2021-10-20 | 住友化学株式会社 | 哺乳動物の発情迅速検査薬 |
WO2023091148A1 (en) * | 2021-11-22 | 2023-05-25 | National Health Research Institutes | ANTI-HSP90α ANTIBODY AND USES THEREOF |
CN114213534B (zh) * | 2022-02-21 | 2022-06-03 | 南京佰抗生物科技有限公司 | 抗人PlGF鼠源单克隆抗体及应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA936260B (en) * | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
GB9519511D0 (en) | 1995-09-25 | 1995-11-29 | Babraham The Inst | Peptides |
JPH1189569A (ja) * | 1997-09-25 | 1999-04-06 | Matsushita Electric Ind Co Ltd | モノクローナル抗体産生細胞ライン及びその作製方法、並びにモノクローナル抗体 |
US20020102613A1 (en) * | 1999-05-18 | 2002-08-01 | Hoogenboom Hendricus Renerus Jacobus Mattheus | Novel Fab fragment libraries and methods for their use |
PL1518863T3 (pl) | 2003-09-26 | 2011-05-31 | Inst Nat De La Rech Agronomique Inra | Przeciwciała modulujące aktywność końskiej gonadotropiny kosmówkowej |
ES2543341T3 (es) * | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
FR2967676B1 (fr) * | 2010-11-19 | 2014-09-19 | Agronomique Inst Nat Rech | Ligand d'hormone luteinisante et complexe ligand-gonadotrophine |
WO2012166198A1 (en) | 2011-05-27 | 2012-12-06 | Abbott Point Of Care Inc. | Tsh antibodies for point-of-care immunoassay formats |
PE20142242A1 (es) * | 2012-03-15 | 2015-01-08 | Janssen Biotech Inc | Anticuerpos humanos anti-cd27, metodos, y usos |
FR3025517B1 (fr) | 2014-09-10 | 2016-12-23 | Repropharm | Ligands potentialisants de la bioactivite des gonadotrophines |
-
2014
- 2014-09-10 FR FR1458469A patent/FR3025517B1/fr active Active
-
2015
- 2015-08-31 FR FR1558078A patent/FR3025518B1/fr active Active
- 2015-09-10 PL PL15771200T patent/PL3191515T3/pl unknown
- 2015-09-10 JP JP2017534009A patent/JP6705608B2/ja active Active
- 2015-09-10 EP EP15770570.8A patent/EP3191514B1/fr active Active
- 2015-09-10 CN CN201580061162.9A patent/CN107108731B/zh active Active
- 2015-09-10 CA CA2960132A patent/CA2960132C/fr active Active
- 2015-09-10 WO PCT/FR2015/052413 patent/WO2016038308A1/fr active Application Filing
- 2015-09-10 WO PCT/FR2015/052414 patent/WO2016038309A1/fr active Application Filing
- 2015-09-10 PL PL15770570T patent/PL3191514T3/pl unknown
- 2015-09-10 EP EP15771200.1A patent/EP3191515B1/fr active Active
- 2015-09-10 AU AU2015314029A patent/AU2015314029C1/en active Active
- 2015-09-10 PT PT157705708T patent/PT3191514T/pt unknown
- 2015-09-10 JP JP2017534010A patent/JP6649385B2/ja active Active
- 2015-09-10 CN CN201580061187.9A patent/CN107108732B/zh active Active
- 2015-09-10 PT PT157712001T patent/PT3191515T/pt unknown
- 2015-09-10 DK DK15771200.1T patent/DK3191515T3/da active
- 2015-09-10 SI SI201531486T patent/SI3191515T1/sl unknown
- 2015-09-10 HU HUE15771200A patent/HUE053100T2/hu unknown
- 2015-09-10 ES ES15771200T patent/ES2845674T3/es active Active
- 2015-09-10 BR BR112017004739-0A patent/BR112017004739B1/pt active IP Right Grant
- 2015-09-10 CA CA2960120A patent/CA2960120C/fr active Active
- 2015-09-10 KR KR1020177009631A patent/KR102072650B1/ko active IP Right Grant
- 2015-09-10 LT LTEP15770570.8T patent/LT3191514T/lt unknown
- 2015-09-10 ES ES15770570T patent/ES2797752T3/es active Active
- 2015-09-10 US US15/510,492 patent/US10703815B2/en active Active
- 2015-09-10 RS RS20210084A patent/RS61358B1/sr unknown
- 2015-09-10 HU HUE15770570A patent/HUE049357T2/hu unknown
- 2015-09-10 US US15/510,640 patent/US10584166B2/en active Active
- 2015-09-10 SI SI201531257T patent/SI3191514T1/sl unknown
- 2015-09-10 DK DK15770570.8T patent/DK3191514T3/da active
- 2015-09-10 LT LTEP15771200.1T patent/LT3191515T/lt unknown
- 2015-09-10 RS RS20200702A patent/RS60501B1/sr unknown
-
2017
- 2017-03-07 IL IL250978A patent/IL250978B2/en unknown
-
2020
- 2020-06-18 HR HRP20200969TT patent/HRP20200969T1/hr unknown
- 2020-06-22 CY CY20201100567T patent/CY1123168T1/el unknown
-
2021
- 2021-01-26 CY CY20211100061T patent/CY1123738T1/el unknown
- 2021-01-26 HR HRP20210141TT patent/HRP20210141T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200969T1 (hr) | Ligandi koji potenciraju bioaktivnost gonadotropina | |
HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
AR109715A1 (es) | Anticuerpos anti-cd27 | |
PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
HRP20201404T1 (hr) | Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita | |
HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
MA47313A (fr) | Formulations sous-cutanées d'anticorps her2 | |
JP2017537971A5 (hr) | ||
PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
JP2016521692A5 (hr) | ||
PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
JP2017533257A5 (hr) | ||
JP2018508483A5 (hr) | ||
AR109298A1 (es) | Anticuerpos multiepitópicos y multivalentes que tienen actividad agonista y métodos de uso | |
RU2017105915A (ru) | Антитела против pd-1 | |
JP2014240385A5 (hr) | ||
PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
JP2019526622A5 (hr) | ||
PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos |